Program
HRS-2129
A development code. Also written as “HRS-2129 Tablet” and “HRS-2129 Tablets”.
In Jiangsu HengRui Medicine's pipeline, Nav1.8
. Its studies are mostly in Pain · Osteoarthritis, Knee · Arthritis, Gouty · Pain, Postoperative · Neuralgia, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 72 open or running | phase 3since Sep 15, 2025 | Sep 23, 2024 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-2129
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2024First study: phase 1 study in PainFirst studyNCT06619392 · 44 enrolled · China
- Dec 16, 2024Phase 1 study in PainNCT06742840 · 23 enrolled · China
- Jan 13, 2025Phase 2 study in Postoperative Pain in OrthopaedicsNCT06780267 · 199 enrolled · China
- Sep 15, 2025Phase 3 study in Postoperative AnalgesiaNCT07185594 · 156 enrolled · China
- Jan 11, 20262 phase 1 studiesNCT07351968, NCT07377721
- Jul 7, 2026Phase 2 study in Acute Gouty ArthritisNCT07706777 · 90 planned · China
TargetBeta
“Nav1.8”the company's pipeline, read by Claude · source
Other programs on SCN10A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
| LY4515100 | Eli Lilly | phase 2 | 3 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07706777Acute Gouty Arthritis · China | 2 | Recruiting | Oct 2026 | 90 |
| NCT07377721Diabetic Peripheral Neuropathic Pain · China | 1 | Recruiting | Sep 2026 | 168 |
| NCT07351968Moderate Pain in Knee Osteoarthritis · China | 1 | Completed | Jul 17, 2026 | 202 |
| NCT07185594Postoperative Analgesia · China | 3 | Completed | Dec 31, 2025 | 156 |
| NCT06780267Postoperative Pain in Orthopaedics · China | 2 | Completed | Mar 19, 2026 | 199 |
| NCT06742840Pain · China | 1 | Completed | Jul 2, 2025 | 23 |
| NCT06619392Pain · China | 1 | Completed | Jan 20, 2025 | 44 |
How it is read
Names in the registry
- “HRS-2129 Tablet”, 3 entries
- “HRS-2129”, 3 entries
- “HRS-2129 Tablets”, 2 entries
Codes read as this program: HRS2129.
Conditions, from the studies’ own filings
- Pain, 2 studies
- Osteoarthritis, Knee, 1 study
- Arthritis, Gouty, 1 study
- Pain, Postoperative, 1 study
- Neuralgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.